These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20646825)

  • 1. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer.
    van Rhijn BW; Zuiverloon TC; Vis AN; Radvanyi F; van Leenders GJ; Ooms BC; Kirkels WJ; Lockwood GA; Boevé ER; Jöbsis AC; Zwarthoff EC; van der Kwast TH
    Eur Urol; 2010 Sep; 58(3):433-41. PubMed ID: 20646825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
    van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
    J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.
    van Rhijn BW; Liu L; Vis AN; Bostrom PJ; Zuiverloon TC; Fleshner NE; van der Aa MN; Alkhateeb SS; Bangma CH; Jewett MA; Zwarthoff EC; Bapat B; van der Kwast TH; Zlotta AR
    BJU Int; 2012 Oct; 110(8):1169-76. PubMed ID: 22448597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.
    Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Ojea A; Portillo J; Montesinos M; Gonzalez M; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA;
    Eur Urol; 2011 Sep; 60(3):423-30. PubMed ID: 21621906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FGFR3 mutation is related to favorable pT1 bladder cancer.
    van Rhijn BW; van der Kwast TH; Liu L; Fleshner NE; Bostrom PJ; Vis AN; Alkhateeb SS; Bangma CH; Jewett MA; Zwarthoff EC; Zlotta AR; Bapat B
    J Urol; 2012 Jan; 187(1):310-4. PubMed ID: 22099989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.
    Burger M; van der Aa MN; van Oers JM; Brinkmann A; van der Kwast TH; Steyerberg EC; Stoehr R; Kirkels WJ; Denzinger S; Wild PJ; Wieland WF; Hofstaedter F; Hartmann A; Zwarthoff EC
    Eur Urol; 2008 Oct; 54(4):835-43. PubMed ID: 18166262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.
    Zuiverloon TC; van der Aa MN; van der Kwast TH; Steyerberg EW; Lingsma HF; Bangma CH; Zwarthoff EC
    Clin Cancer Res; 2010 Jun; 16(11):3011-8. PubMed ID: 20404005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
    van der Aa MN; Zwarthoff EC; Steyerberg EW; Boogaard MW; Nijsen Y; van der Keur KA; van Exsel AJ; Kirkels WJ; Bangma C; van der Kwast TH
    Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.
    Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Amorós A; Tardón A; Carrato A; Serra C; Malats N; Real FX
    J Clin Oncol; 2006 Aug; 24(22):3664-71. PubMed ID: 16877735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables.
    Ather MH; Zaidi M
    Urol J; 2009; 6(3):189-93. PubMed ID: 19711273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables.
    Altieri VM; Castellucci R; Palumbo P; Verratti V; Sut M; Olivieri R; Manco R; Ricciardulli S; Nicolai M; Criniti P; Tenaglia RL
    Urol Int; 2012; 89(1):61-6. PubMed ID: 22722366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer.
    van Rhijn BW
    Urol Oncol; 2012; 30(4):518-23. PubMed ID: 22742564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.
    Kompier LC; van der Aa MN; Lurkin I; Vermeij M; Kirkels WJ; Bangma CH; van der Kwast TH; Zwarthoff EC
    J Pathol; 2009 May; 218(1):104-12. PubMed ID: 19156776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.
    Gudjónsson S; Adell L; Merdasa F; Olsson R; Larsson B; Davidsson T; Richthoff J; Hagberg G; Grabe M; Bendahl PO; Månsson W; Liedberg F
    Eur Urol; 2009 Apr; 55(4):773-80. PubMed ID: 19153001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
    Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
    Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.
    Bodoor K; Ghabkari A; Jaradat Z; Alkhateeb A; Jaradat S; Al-Ghazo MA; Matalka I; Musleh H; Haddad Y
    Cancer Epidemiol; 2010 Dec; 34(6):724-32. PubMed ID: 20542753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers.
    Novara G; De Marco V; Gottardo F; Dalpiaz O; Bouygues V; Galfano A; Martignoni G; Patard JJ; Artibani W; Ficarra V
    Cancer; 2007 Oct; 110(8):1715-22. PubMed ID: 17724728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.
    Lamy A; Gobet F; Laurent M; Blanchard F; Varin C; Moulin C; Andreou A; Frebourg T; Pfister C
    J Urol; 2006 Dec; 176(6 Pt 1):2686-9. PubMed ID: 17085196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.